Back to discover
Disease

Urinary Incontinence

Late-stage therapeutic developmentEmerging research
1
Publications
18
Clinical trials
2026
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Research Highlights1View
Clinical Milestones11View all 11
+3 more in the activity timeline below
Activity timeline12

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies

Approval — Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency… (2007)

Approval — Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency… (2004)

Approval — Yentreve is indicated for women for the treatment of moderate to severe stress urinary in… (2004)

Oxybutyninapproved

Approval — Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency… (2004)

Clinical trials

17 sponsors · 2 new · 2 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
18
All trials
6
Active
17
Late-stage
6
Completed
Late-stage studies
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2007emaApprovalFesoterodine fumarate· Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome. source ↗
2004emaApprovalDarifenacin hydrobromide· Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome. source ↗
2004emaApprovalDuloxetine Hydrochloride· Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI). source ↗
2004emaApprovalOxybutynin· Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes6
  • Electric Stimulation Therapy1
  • Urethra1
  • Urinary Incontinence1
  • Urinary Incontinence, Stress1
  • Urinary Incontinence, Urge1
  • Wireless Technology1
Leading journals1
  • Nature communications1
Leading researchers8
  • Gao Q1
  • Kang N1
  • Lee CHT1
  • Liu M1
  • Ma C1
  • Shao L1
  • Shao Y1
  • Sitti M1
Affiliations (unnormalised)6
  • Global College1
  • Lee Kong Chian School of Medicine1
  • Max Planck Institute for Intelligent Systems1
  • Ruijin Hospital1
  • School of Electrical and Electronic Engineering1
  • School of Electrical Engineering1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Involuntary loss of URINE, such as leaking of urine. It is a symptom of various underlying pathological processes. Major types of incontinence include URINARY URGE INCONTINENCE and URINARY STRESS INCONTINENCE.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.